| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 130 | 167 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -14,524 | -11,564 |
| Cash and cash equivalents at beginning of period | 40,493 | - |
| Cash and cash equivalents at end of period | 25,969 | - |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)